Opinion
Video
Author(s):
Stephanie L. Graff, MD, provides an overview of ESR1 mutations in ER+/HER2- metastatic breast cancer, highlighting their prevalence, clinical implications, and challenges.
FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
Identifying Patients With Low-Risk Breast Cancer for De-escalated Therapy
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
Impact of Sexual Counseling on Women With Breast Cancer
Alcohol and Cancer: Murthy’s Urgent Call